Show simple item record

dc.contributor.authorSchuerle, Simone
dc.contributor.authorFurubayashi, Maiko
dc.contributor.authorSoleimany, Ava P.
dc.contributor.authorGwisai, Tinotenda
dc.contributor.authorHuang, Wei
dc.contributor.authorVoigt, Christopher A.
dc.contributor.authorBhatia, Sangeeta N
dc.date.accessioned2020-05-28T21:41:34Z
dc.date.available2020-05-28T21:41:34Z
dc.date.issued2020-02
dc.date.submitted2019-10
dc.identifier.urihttps://hdl.handle.net/1721.1/125569
dc.description.abstractTumor-selective contrast agents have the potential to aid in the diagnosis and treatment of cancer using noninvasive imaging modalities such as magnetic resonance imaging (MRI). Such contrast agents can consist of magnetic nanoparticles incorporating functionalities that respond to cues specific to tumor environments. Genetically engineering magnetotactic bacteria to display peptides has been investigated as a means to produce contrast agents that combine the robust image contrast effects of magnetosomes with the transgenic-targeting peptides displayed on their surface. This work reports the first use of magnetic nanoparticles that display genetically encoded pH low insertion peptide (pHLIP), a long peptide intended to enhance MRI contrast by targeting the extracellular acidity associated with the tumors. To demonstrate the modularity of this versatile platform to incorporate diverse targeting ligands by genetic engineering, we also incorporated the cyclic αv integrin-binding peptide iRGD into separate magnetosomes. Specifically, we investigate their potential for enhanced binding and tumor imaging both in vitro and in vivo. Our experiments indicate that these tailored magnetosomes retain their magnetic properties, making them well suited as T2 contrast agents, while exhibiting an increased binding compared to the binding in wild-type magnetosomes.en_US
dc.description.sponsorshipU.S. Army Research Office (Contract W911NF-09-0001)en_US
dc.description.sponsorshipU.S. Army Research Office (Grant W911NF-19-2-0026)en_US
dc.description.sponsorshipNational Cancer Institute (Grant P30-CA14051)en_US
dc.description.sponsorshipNational Institute of Environmental Health Sciences (Grant P30-ES002109)en_US
dc.language.isoen
dc.publisherAmerican Chemical Society (ACS)en_US
dc.relation.isversionofhttp://dx.doi.org/10.1021/acssynbio.9b00416en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourcebioRxiven_US
dc.titleGenetic Encoding of Targeted Magnetic Resonance Imaging Contrast Agents for Tumor Imagingen_US
dc.typeArticleen_US
dc.identifier.citationSchuerle, Simone et al. "Genetic Encoding of Targeted Magnetic Resonance Imaging Contrast Agents for Tumor Imaging." ACS Synthetic Biology 9, 2 (February 2020): 392–401 © 2020 American Chemical Societyen_US
dc.contributor.departmentDavid H. Koch Institute for Integrative Cancer Research at MITen_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.contributor.departmentMassachusetts Institute of Technology. Research Laboratory of Electronicsen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Electrical Engineering and Computer Scienceen_US
dc.contributor.departmentBroad Institute of MIT and Harvarden_US
dc.contributor.departmentMassachusetts Institute of Technology. Synthetic Biology Centeren_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.relation.journalACS Synthetic Biologyen_US
dc.eprint.versionOriginal manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/NonPeerRevieweden_US
dc.date.updated2020-03-18T15:05:31Z
dspace.date.submission2020-03-18T15:05:49Z
mit.journal.volume9en_US
mit.journal.issue2en_US
mit.licensePUBLISHER_POLICY


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record